Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the Global Live Biotherapeutic Product (LBP) Market (By Type of Product(Probiotic drugs, Other drugs), By Type of Molecule(Biologics, Small molecules), By Target disease indication(Necrotizing Enterocolitis, Graft Versus Host Disease, Recurrent C. difficile Infection, Primary Hyperoxaluria, Others), By Therapeutic area (Infectious Diseases, Digestive and Gastrointestinal Disorders, Rare Disorders, Others), By route of administration(Rectal therapeutics, Oral therapeutics)- Market Outlook and Industry Analysis 2030″

According to the latest research by Insight Analytics, the Global Live Biotherapeutic Product (LBP) Market is worth US$ 355.9 Million in 2021 and is predicted to reach US$ 2608.0 Million in 2030, with a promising CAGR of 25.2%  during the forecast period of 2022 to 2030.

Request for Sample Pages:

Live biotherapeutics are a relatively new category of drugs that contain living things like bacteria. These live microbiome drugs can be used to treat a variety of ailments and can prevent, treat, and even cure human disease issues. Among these treatments, there is no category for vaccinations. These microbes produce and ingest a wide range of chemicals that have a big impact on human health and wellbeing. Reintroducing beneficial microbes may function as therapeutically effective therapy for restoring and sustaining a healthy microbiome. By touching the local ecosystem, other microbes, and their communications with the host, LBPs will have a biological impact.

Throughout the forecast period, increasing R&D activities and a growing pipeline of microbiome-targeting medicines, which are anticipated to treat a broad range of serious diseases, are likely to be the primary drivers of market expansion. The market is developing due to advancing technology, innovation in developing new pharmaceuticals, and clinical trial efforts to cure disorders. Due to rising government funding levels and an increased R&D budget for medication development, significant growth potential is anticipated during the forecast period. More than 640 patents for microbiome therapeutics have been approved in the previous two years. Due to a lack of specialized infrastructure, relevant expertise, and significant capital expenditure, ensuring compliance with good manufacturing practices (GMP), associated safety risks with LBPs, and capacity issues can be challenging. We expect that these factors will restrict the market growth.

Due to the significant burden of bacterial infection disease and the increasing demand for novel, cutting-edge therapies, North America is predicted to contribute to the Live Biotherapeutic Product (LBP) market over the forecast years. Businesses receive significant funding to create new goods and investigate live biotherapeutic components. Additionally, the Asia Pacific Live Biotherapeutic Product (LBP) market is anticipated to expand considerably throughout the projected period. A rising number of contract manufacturing arrangements among numerous developers is predicted to provide significant opportunities for market expansion.

Enquiry Before Buying:


The key players in live biotherapeutic products industry are Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals), Sciotio Biosciences Inc, Seres Therapeutics, Inc., BrickBuilt Therapeutics,  Microbiotica, Enterome, AOBiome Therapeutics, Inc., BiomX,  Destiny Pharma plc, Ferring Pharmaceuticals, Nexbiome, Finch Therapeutics Group, Inc, MaaT Pharma, Vedanta Biosciences Inc., OxThera AB, Pendulum Therapeutics, Biomica Ltd., Caelus Health, Quorum Innovations, Sanofi S.A, OptiBiotix Health Plc,  DermBiont, Inc., EnteroBiotix Ltd, YSOPIA Bioscience, Johnson and Johnson Inc.,  Winclove Probiotics, Takeda Pharmaceutical Co. Ltd., Second Genome Therapeutics, TargEDys, Evelo Biosciences, Inc., Scioto Biosciences, Inc., Lactobio A/S, Immuron Limited, PureTech Health Plc, Synthetic Biologics, ExeGi Pharma, Mybiotics Pharma LTD, 4D pharma plc, Siolta Therapeutics, Axial Therapeutics, Inc.,  Stellate Therapeutics, Rise Therapeutics, EverImmune S.A. and others.


Recent market partnerships and agreements:

In March 2022, The largest microbiome-related fundraising deal in Europe was completed by Microbiotica for £50 million ($67 million). The Phase 1b clinical investigations for the two primary oral Live Bacterial Therapeutics (LBTs) from Microbiotica, MB097 and MB310, will also be advanced, as well as LBTs for new diseases.

In November 2021, Bacthera and Seres Therapeutics will work together to market SER-109, a possible treatment for recurrent C. difficile infection. The contract stipulates that Bacthera would build a commercial manufacturing facility specifically for the production of LBPs in its new Microbiome Center of Excellence on Lonza’s Ibex campus in Visp, Switzerland.

Interested in learning more about this most recent version of the report? Visit @


Market Segmentation

Global Live Biotherapeutic Product (LBP) Market, by Type Of Product, 2022-2030 (Value US$ Mn)

  • Probiotic Drugs
  • Other Drugs

Global Live Biotherapeutic Product (LBP) Market, by Type of Molecule, 2022-2030 (Value US$ Mn)

  • Biologics
  • Small Molecules

Global Live Biotherapeutic Product (LBP) Market, by Target disease indication, 2022-2030 (Value US$ Mn)

  • Recurrent C. difficile Infection
  • Graft Versus Host Disease
  • Primary Hyperoxaluria
  • Necrotizing Enterocolitis
  • Others

Global Live Biotherapeutic Product (LBP) Market, by Therapeutic area, 2022-2030 (Value US$ Mn)

  • Rare Disorders
  • Digestive and Gastrointestinal Disorders
  • Rare Disorders
  • Infectious Diseases
  • Others

Global Live Biotherapeutic Product (LBP) Market, by Route of administration, 2022-2030 (Value US$ Mn)

  • Rectal Therapeutics
  • Oral Therapeutics

Global Live Biotherapeutic Product (LBP) Market, by Region, 2022-2030 (Value US$ Mn)

  • Europe
  • North America
  • Latin America
  • Asia Pacific
  • Middle East & Africa

North America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • Canada
  • U.S.

Europe Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • Spain
  • Germany
  • Russia
  • France
  • Italy
  • Rest of Europe

Asia Pacific Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • Japan
  • India
  • China
  • South Korea
  • Australia & New Zealand

Latin America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

Middle East & Africa Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for the global Live Biotherapeutic Product (LBP) market
  • To receive an industry overview and future trends in the Live Biotherapeutic Product (LBP) market
  • To analyze the Live Biotherapeutic Product (LBP) market drivers and challenges
  • To get information on the Live Biotherapeutic Product (LBP) market value (US$Mn) forecast to 2030
  • To get information on investments, mergers & acquisitions in the Live Biotherapeutic Product (LBP) market industry

For More Customization @

Tags: Clinical Trial, growth rate, Microbiome, market, pipeline, FDA Approval, Competative Landscape, New Product LAunch, Live Biotherapeutic, LiveBiotherapeutic, Revenue Forecast, Microbiome Therapeutic, Microbiome Drug

See Campaign:

Contact Information:

InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ Follow Us On Facebook @

Financial Content, PR-Wirein, Extended Distribution, iCN Internal Distribution, Research Newswire, English